To find out how noncancerous cells react to the treatment with ActD + Nut3a + FASLG, we compared how normal human fibroblasts (GM07492) and lung cancer cells (A549) grow after pre-treatment with ActD + Nut3a with subsequent exposure to FASLG (Fig. 10A). The gene discussed is FASLG; the disease is lung cancer.